In radiotherapy resistance, PTBP1 promotes switching from DNMT3B‐S to DNMT3B‐L, suppressing DUSP2 and enhancing radioresistance in prostate cancer [303]. This evidence concerns the gene DNMT3B and prostate carcinoma.